A concise news article previewing early human safety testing of a new oral drug aimed at weight and metabolic support, inviting readers curious about clinical-stage metabolic therapeutics.
Key Takeaways
- Enveda completed a first-in-human trial enrolling 88 healthy adults to assess safety and pharmacology
- ENV-308 was reportedly well tolerated across the tested dose range with no serious adverse events
- Participants showed reductions in circulating leptin, largest in those with higher baseline leptin